Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Rheumatology

Topics

Medicine

Immunology

Pathology

Internal Medicine

Rheumatology

Show all topics

DOI

10.1016/s2665-9913(24)00246-7